Key Takeaways IDEXX posted 11% organic growth in international CAG diagnostic recurring revenues in Q2 2025.IDXX's cloud-native PIMS platforms ezyVet and Neo saw double-digit placement growth in the second quarter.IDEXX ended Q2 2025 with $164.6M in cash versus $654M in short-term debt and $450M long-term debt.IDEXX Laboratories, Inc.’s (IDXX) second-quarter growth was backed by the robust performance of its CAG (Companion Animal Group) Diagnostics business. The consistent growth in international CAG diagno ...

Key Takeaways IDEXX stock has risen 56.2% year to date, far outpacing its industry and the S&P 500.IDEXX's international CAG diagnostic revenues rose 11% in Q2, with strong gains in consumables.IDXX's cloud-native platforms like ezyVet, Neo and Vello delivered double-digit growth in Q2.IDEXX Laboratories (IDXX) has witnessed strong momentum year to date. Shares of the company have risen 56.2%, outperforming the 6.8% decline of the industry during the same time frame. The S&P 500 composite has increased 9.8% ...